Risk Factors for Unfavorable Functional Outcome after Endovascular Treatment of Cerebral Vasospasm following Aneurysmal Subarachnoid Hemorrhage

Cerebral vasospasm remains a strong predictor of poor outcomes after aneurysmal subarachnoid hemorrhage (aSAH). Endovascular treatment of vasospasm can be considered when conservative treatment options are exhausted, but its superiority over standard treatment remains a subject of critical debate. T...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of neuroradiology : AJNR Vol. 46; no. 3; pp. 495 - 501
Main Authors Thaler, Christian, Tokareva, Bogdana, Wentz, Rabea, Heitkamp, Christian, Bechstein, Matthias, van Horn, Noel, Geest, Vincent, Dührsen, Lasse, Meyer, Hanno S., Bester, Maxim, Fiehler, Jens, Meyer, Lukas
Format Journal Article
LanguageEnglish
Published United States 04.03.2025
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Cerebral vasospasm remains a strong predictor of poor outcomes after aneurysmal subarachnoid hemorrhage (aSAH). Endovascular treatment of vasospasm can be considered when conservative treatment options are exhausted, but its superiority over standard treatment remains a subject of critical debate. This study focuses on patients with clinically relevant vasospasm after aSAH who underwent endovascular vasospasm treatment and aims to analyze patients' individual risk factors, intensity, and extent of cerebral vasospasm associated with poor functional outcomes after aSAH. We conducted a retrospective cohort study of consecutive patients with aSAH admitted at a tertiary stroke center between January 2016 and December 2022. Patients with medically refractory cerebral vasospasm necessitating at least 1 endovascular intervention were analyzed. Primary end point was defined as functional outcome defined as modified Rankin Scale (mRS) scores after 6 months. Secondary end point was the occurrence of cerebral infarctions following cerebral vasospasm. Overall, 138 patients received endovascular treatment due to cerebral vasospasm, including 322 treatments, with 78 patients receiving more than 1 endovascular treatment. In 65.2% (90) of patients, cerebral vasospasm developed in both hemispheres; in 16.7% (23), cerebral vasospasm occurred involving the posterior circulation; and in 10.1% (14), percutaneous transluminal angioplasty was performed. Multivariable logistic regression analysis showed an association of higher age (adjusted odds ratio [aOR], 1.05, 95% CI: 1.0-1.1), higher Hunt and Hess grades (aOR, 2.12, 95% CI: 1.38-3.24), the occurrence of rebleeding (aOR, 4.97, 95% CI: 1.0-24.65), and bihemispheric vasospasm (aOR, 4.05, 95% CI: 1.4-11.72) with unfavorable outcome (mRS 3-6). Further analysis showed that higher age (aOR, 1.07, 95% CI: 1.03-1.13) was associated with an increased risk of developing vasospasm-associated infarctions. Our results indicate an association between bihemispheric cerebral vasospasm and poor functional outcomes after aSAH. This finding supports a more aggressive treatment strategy in patients developing bihemispheric vasospasm to prevent unfavorable disease courses.
AbstractList Cerebral vasospasm remains a strong predictor of poor outcomes after aneurysmal subarachnoid hemorrhage (aSAH). Endovascular treatment of vasospasm can be considered when conservative treatment options are exhausted, but its superiority over standard treatment remains a subject of critical debate. This study focuses on patients with clinically relevant vasospasm after aSAH who underwent endovascular vasospasm treatment and aims to analyze patients' individual risk factors, intensity, and extent of cerebral vasospasm associated with poor functional outcomes after aSAH.BACKGROUND AND PURPOSECerebral vasospasm remains a strong predictor of poor outcomes after aneurysmal subarachnoid hemorrhage (aSAH). Endovascular treatment of vasospasm can be considered when conservative treatment options are exhausted, but its superiority over standard treatment remains a subject of critical debate. This study focuses on patients with clinically relevant vasospasm after aSAH who underwent endovascular vasospasm treatment and aims to analyze patients' individual risk factors, intensity, and extent of cerebral vasospasm associated with poor functional outcomes after aSAH.We conducted a retrospective cohort study of consecutive patients with aSAH admitted at a tertiary stroke center between January 2016 and December 2022. Patients with medically refractory cerebral vasospasm necessitating at least 1 endovascular intervention were analyzed. Primary end point was defined as functional outcome defined as modified Rankin Scale (mRS) scores after 6 months. Secondary end point was the occurrence of cerebral infarctions following cerebral vasospasm.MATERIALS AND METHODSWe conducted a retrospective cohort study of consecutive patients with aSAH admitted at a tertiary stroke center between January 2016 and December 2022. Patients with medically refractory cerebral vasospasm necessitating at least 1 endovascular intervention were analyzed. Primary end point was defined as functional outcome defined as modified Rankin Scale (mRS) scores after 6 months. Secondary end point was the occurrence of cerebral infarctions following cerebral vasospasm.Overall, 138 patients received endovascular treatment due to cerebral vasospasm, including 322 treatments, with 78 patients receiving more than 1 endovascular treatment. In 65.2% (90) of patients, cerebral vasospasm developed in both hemispheres; in 16.7% (23), cerebral vasospasm occurred involving the posterior circulation; and in 10.1% (14), percutaneous transluminal angioplasty was performed. Multivariable logistic regression analysis showed an association of higher age (adjusted odds ratio [aOR], 1.05, 95% CI: 1.0-1.1), higher Hunt and Hess grades (aOR, 2.12, 95% CI: 1.38-3.24), the occurrence of rebleeding (aOR, 4.97, 95% CI: 1.0-24.65), and bihemispheric vasospasm (aOR, 4.05, 95% CI: 1.4-11.72) with unfavorable outcome (mRS 3-6). Further analysis showed that higher age (aOR, 1.07, 95% CI: 1.03-1.13) was associated with an increased risk of developing vasospasm-associated infarctions.RESULTSOverall, 138 patients received endovascular treatment due to cerebral vasospasm, including 322 treatments, with 78 patients receiving more than 1 endovascular treatment. In 65.2% (90) of patients, cerebral vasospasm developed in both hemispheres; in 16.7% (23), cerebral vasospasm occurred involving the posterior circulation; and in 10.1% (14), percutaneous transluminal angioplasty was performed. Multivariable logistic regression analysis showed an association of higher age (adjusted odds ratio [aOR], 1.05, 95% CI: 1.0-1.1), higher Hunt and Hess grades (aOR, 2.12, 95% CI: 1.38-3.24), the occurrence of rebleeding (aOR, 4.97, 95% CI: 1.0-24.65), and bihemispheric vasospasm (aOR, 4.05, 95% CI: 1.4-11.72) with unfavorable outcome (mRS 3-6). Further analysis showed that higher age (aOR, 1.07, 95% CI: 1.03-1.13) was associated with an increased risk of developing vasospasm-associated infarctions.Our results indicate an association between bihemispheric cerebral vasospasm and poor functional outcomes after aSAH. This finding supports a more aggressive treatment strategy in patients developing bihemispheric vasospasm to prevent unfavorable disease courses.CONCLUSIONSOur results indicate an association between bihemispheric cerebral vasospasm and poor functional outcomes after aSAH. This finding supports a more aggressive treatment strategy in patients developing bihemispheric vasospasm to prevent unfavorable disease courses.
Cerebral vasospasm remains a strong predictor of poor outcomes after aneurysmal subarachnoid hemorrhage (aSAH). Endovascular treatment of vasospasm can be considered when conservative treatment options are exhausted, but its superiority over standard treatment remains a subject of critical debate. This study focuses on patients with clinically relevant vasospasm after aSAH who underwent endovascular vasospasm treatment and aims to analyze patients' individual risk factors, intensity, and extent of cerebral vasospasm associated with poor functional outcomes after aSAH. We conducted a retrospective cohort study of consecutive patients with aSAH admitted at a tertiary stroke center between January 2016 and December 2022. Patients with medically refractory cerebral vasospasm necessitating at least 1 endovascular intervention were analyzed. Primary end point was defined as functional outcome defined as modified Rankin Scale (mRS) scores after 6 months. Secondary end point was the occurrence of cerebral infarctions following cerebral vasospasm. Overall, 138 patients received endovascular treatment due to cerebral vasospasm, including 322 treatments, with 78 patients receiving more than 1 endovascular treatment. In 65.2% (90) of patients, cerebral vasospasm developed in both hemispheres; in 16.7% (23), cerebral vasospasm occurred involving the posterior circulation; and in 10.1% (14), percutaneous transluminal angioplasty was performed. Multivariable logistic regression analysis showed an association of higher age (adjusted odds ratio [aOR], 1.05, 95% CI: 1.0-1.1), higher Hunt and Hess grades (aOR, 2.12, 95% CI: 1.38-3.24), the occurrence of rebleeding (aOR, 4.97, 95% CI: 1.0-24.65), and bihemispheric vasospasm (aOR, 4.05, 95% CI: 1.4-11.72) with unfavorable outcome (mRS 3-6). Further analysis showed that higher age (aOR, 1.07, 95% CI: 1.03-1.13) was associated with an increased risk of developing vasospasm-associated infarctions. Our results indicate an association between bihemispheric cerebral vasospasm and poor functional outcomes after aSAH. This finding supports a more aggressive treatment strategy in patients developing bihemispheric vasospasm to prevent unfavorable disease courses.
Author Thaler, Christian
Tokareva, Bogdana
Bechstein, Matthias
Meyer, Hanno S.
Heitkamp, Christian
Meyer, Lukas
van Horn, Noel
Bester, Maxim
Wentz, Rabea
Dührsen, Lasse
Geest, Vincent
Fiehler, Jens
Author_xml – sequence: 1
  givenname: Christian
  orcidid: 0000-0002-7102-9316
  surname: Thaler
  fullname: Thaler, Christian
– sequence: 2
  givenname: Bogdana
  orcidid: 0000-0003-1946-1782
  surname: Tokareva
  fullname: Tokareva, Bogdana
– sequence: 3
  givenname: Rabea
  surname: Wentz
  fullname: Wentz, Rabea
– sequence: 4
  givenname: Christian
  orcidid: 0000-0002-8988-0918
  surname: Heitkamp
  fullname: Heitkamp, Christian
– sequence: 5
  givenname: Matthias
  orcidid: 0000-0002-5652-7499
  surname: Bechstein
  fullname: Bechstein, Matthias
– sequence: 6
  givenname: Noel
  orcidid: 0000-0001-5764-1982
  surname: van Horn
  fullname: van Horn, Noel
– sequence: 7
  givenname: Vincent
  surname: Geest
  fullname: Geest, Vincent
– sequence: 8
  givenname: Lasse
  surname: Dührsen
  fullname: Dührsen, Lasse
– sequence: 9
  givenname: Hanno S.
  orcidid: 0000-0002-4576-1239
  surname: Meyer
  fullname: Meyer, Hanno S.
– sequence: 10
  givenname: Maxim
  orcidid: 0000-0003-4007-5755
  surname: Bester
  fullname: Bester, Maxim
– sequence: 11
  givenname: Jens
  orcidid: 0000-0001-8533-7478
  surname: Fiehler
  fullname: Fiehler, Jens
– sequence: 12
  givenname: Lukas
  orcidid: 0000-0002-3776-638X
  surname: Meyer
  fullname: Meyer, Lukas
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40015973$$D View this record in MEDLINE/PubMed
BookMark eNo9kctu2zAQRYkiReOk3fQDCi6LAEpJiXpwaRh2HCBAgOaB7oQhObLlSqQ7lBLkK_LLkRu3qxlgzpzFvWfsxAePjH2V4jKTpfoBO0-X8yqX8gObSZ0Vic71rxM2E1LnSSFFdcrOYtwJIXJdpp_YqRJCTms2Y68_2_ibr8AOgSJvAvEH38BTIDAd8tXo7dAGDx2_HQcbeuTQDEh86V14gmjHDojfE8LQox94aPgCCQ1ND48QQ9xD7Cdr14Xn1m_43ONIL7GfznejAQK79aF1fI19INrCBj-zjw10Eb8c5zl7WC3vF-vk5vbqejG_SWyqiiFBbdBVRgoJoBBsZbDQNsVGahS6UE42mcuFAVtWRmibiyJVCp1DB2WqdXbOvr979xT-jBiHum-jxa4Dj2GM9RRsmhaVSssJ_XZER9Ojq_fU9kAv9b8QJ-DiHbAUYiRs_iNSHESqPjRU_20oewNheofd
Cites_doi 10.3174/ajnr.A5024
10.1016/j.wneu.2018.01.156
10.1212/WNL.0000000000007862
10.1016/j.ijsu.2014.07.013
10.1016/S1474-4422(06)70412-4
10.1161/STROKEAHA.110.597914
10.3174/ajnr.A8249
10.1038/jcbfm.2008.74
10.1161/STROKEAHA.110.589275
10.1016/j.wneu.2018.07.138
10.1161/STROKEAHA.107.484360
10.1007/s00062-018-0711-3
10.1007/s00062-022-01151-4
10.1007/s00330-016-4702-y
10.1007/s12028-022-01545-9
10.1136/jnis-2022-019016
10.1161/STR.0000000000000436
10.1007/s00330-018-5505-0
10.1016/j.neurad.2018.04.001
10.1136/jnis-2022-019272
10.1007/s12028-011-9600-1
10.3390/jcm11206197
10.1161/JAHA.121.021845
10.3389/fneur.2021.688362
10.1227/01.NEU.0000156644.45384.92
ContentType Journal Article
Copyright 2025 by American Journal of Neuroradiology.
Copyright_xml – notice: 2025 by American Journal of Neuroradiology.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.3174/ajnr.A8511
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1936-959X
EndPage 501
ExternalDocumentID 40015973
10_3174_ajnr_A8511
Genre Journal Article
GroupedDBID ---
.55
.GJ
23M
2WC
53G
5GY
5RE
5VS
6J9
AAEJM
AAYXX
ACGFO
ACIWK
ACPRK
ADBBV
AENEX
AFFNX
AFHIN
AFRAH
AJJEV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BTFSW
C1A
CITATION
CS3
E3Z
EBS
EJD
EMOBN
F5P
F9R
GX1
H13
INIJC
KQ8
MV1
N9A
OK1
P2P
P6G
R0Z
RHI
RPM
TNE
TR2
UDS
W8F
WOQ
WOW
X7M
ZCG
ZGI
ZXP
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c246t-e9bed8b101aa4eac8be69c2ef19e0964d1f3d50bac78b09c506244eddeda72993
ISSN 0195-6108
1936-959X
IngestDate Fri Jul 11 07:22:18 EDT 2025
Thu Jul 10 06:32:49 EDT 2025
Tue Jul 01 04:55:41 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
License 2025 by American Journal of Neuroradiology.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c246t-e9bed8b101aa4eac8be69c2ef19e0964d1f3d50bac78b09c506244eddeda72993
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-7102-9316
0000-0002-3776-638X
0000-0002-8988-0918
0000-0001-5764-1982
0000-0003-4007-5755
0000-0002-5652-7499
0000-0003-1946-1782
0000-0002-4576-1239
0000-0001-8533-7478
PMID 40015973
PQID 3172268427
PQPubID 23479
PageCount 7
ParticipantIDs proquest_miscellaneous_3172268427
pubmed_primary_40015973
crossref_primary_10_3174_ajnr_A8511
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2025-Mar-04
PublicationDateYYYYMMDD 2025-03-04
PublicationDate_xml – month: 03
  year: 2025
  text: 2025-Mar-04
  day: 04
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle American journal of neuroradiology : AJNR
PublicationTitleAlternate AJNR Am J Neuroradiol
PublicationYear 2025
References 2025050715550584000_46.3.495.19
2025050715550584000_46.3.495.18
2025050715550584000_46.3.495.17
2025050715550584000_46.3.495.16
2025050715550584000_46.3.495.15
2025050715550584000_46.3.495.14
2025050715550584000_46.3.495.13
2025050715550584000_46.3.495.12
2025050715550584000_46.3.495.11
2025050715550584000_46.3.495.10
2025050715550584000_46.3.495.2
2025050715550584000_46.3.495.3
2025050715550584000_46.3.495.1
2025050715550584000_46.3.495.8
2025050715550584000_46.3.495.9
2025050715550584000_46.3.495.6
2025050715550584000_46.3.495.7
2025050715550584000_46.3.495.4
2025050715550584000_46.3.495.5
2025050715550584000_46.3.495.26
2025050715550584000_46.3.495.25
2025050715550584000_46.3.495.24
2025050715550584000_46.3.495.23
2025050715550584000_46.3.495.22
2025050715550584000_46.3.495.21
2025050715550584000_46.3.495.20
References_xml – ident: 2025050715550584000_46.3.495.21
  doi: 10.3174/ajnr.A5024
– ident: 2025050715550584000_46.3.495.22
  doi: 10.1016/j.wneu.2018.01.156
– ident: 2025050715550584000_46.3.495.23
  doi: 10.1212/WNL.0000000000007862
– ident: 2025050715550584000_46.3.495.10
  doi: 10.1016/j.ijsu.2014.07.013
– ident: 2025050715550584000_46.3.495.19
  doi: 10.1016/S1474-4422(06)70412-4
– ident: 2025050715550584000_46.3.495.2
  doi: 10.1161/STROKEAHA.110.597914
– ident: 2025050715550584000_46.3.495.11
  doi: 10.3174/ajnr.A8249
– ident: 2025050715550584000_46.3.495.24
– ident: 2025050715550584000_46.3.495.14
  doi: 10.1038/jcbfm.2008.74
– ident: 2025050715550584000_46.3.495.12
  doi: 10.1161/STROKEAHA.110.589275
– ident: 2025050715550584000_46.3.495.6
  doi: 10.1016/j.wneu.2018.07.138
– ident: 2025050715550584000_46.3.495.15
  doi: 10.1161/STROKEAHA.107.484360
– ident: 2025050715550584000_46.3.495.4
  doi: 10.1007/s00062-018-0711-3
– ident: 2025050715550584000_46.3.495.25
  doi: 10.1007/s00062-022-01151-4
– ident: 2025050715550584000_46.3.495.9
  doi: 10.1007/s00330-016-4702-y
– ident: 2025050715550584000_46.3.495.18
  doi: 10.1007/s12028-022-01545-9
– ident: 2025050715550584000_46.3.495.20
  doi: 10.1136/jnis-2022-019016
– ident: 2025050715550584000_46.3.495.3
  doi: 10.1161/STR.0000000000000436
– ident: 2025050715550584000_46.3.495.16
  doi: 10.1007/s00330-018-5505-0
– ident: 2025050715550584000_46.3.495.26
  doi: 10.1016/j.neurad.2018.04.001
– ident: 2025050715550584000_46.3.495.5
  doi: 10.1136/jnis-2022-019272
– ident: 2025050715550584000_46.3.495.7
  doi: 10.1007/s12028-011-9600-1
– ident: 2025050715550584000_46.3.495.8
  doi: 10.3390/jcm11206197
– ident: 2025050715550584000_46.3.495.13
  doi: 10.1161/JAHA.121.021845
– ident: 2025050715550584000_46.3.495.17
  doi: 10.3389/fneur.2021.688362
– ident: 2025050715550584000_46.3.495.1
  doi: 10.1227/01.NEU.0000156644.45384.92
SSID ssj0005972
Score 2.461744
Snippet Cerebral vasospasm remains a strong predictor of poor outcomes after aneurysmal subarachnoid hemorrhage (aSAH). Endovascular treatment of vasospasm can be...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
StartPage 495
SubjectTerms Adult
Aged
Endovascular Procedures
Female
Humans
Male
Middle Aged
Retrospective Studies
Risk Factors
Subarachnoid Hemorrhage - complications
Subarachnoid Hemorrhage - diagnostic imaging
Subarachnoid Hemorrhage - therapy
Treatment Outcome
Vasospasm, Intracranial - diagnostic imaging
Vasospasm, Intracranial - etiology
Vasospasm, Intracranial - surgery
Vasospasm, Intracranial - therapy
Title Risk Factors for Unfavorable Functional Outcome after Endovascular Treatment of Cerebral Vasospasm following Aneurysmal Subarachnoid Hemorrhage
URI https://www.ncbi.nlm.nih.gov/pubmed/40015973
https://www.proquest.com/docview/3172268427
Volume 46
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtNAEF2FIlV9QdwpNy2CN-QS22vX-1ihRlFRi6gS1Ddr1x43oYkdOU4R_AQ_wkcys15fWqgEvFiR7ew6Pidz29kZxt5k4KVumngO-NnQEUEWOVqK0FGZ8FzwE6mB4pDHJ-F4Ko7OgrPB4Gcva2lT6b3k-x_3lfwPqngOcaVdsv-AbDsonsDPiC8eEWE8_hXGp5QXPrIdcyhfcJpn6hJBpe1QI9RYNtD3cVPh9GAbgh_maZeAOmkTzSkvA0paR168_azWBYqa9RJHXSyKryZ2QqUvv62XVD5kQ2sUFJOfp6i4lkVZztTVpKJ2JahXmsLUzixVaus-mZjk0Um71DSZqWZb4syKni4GfqFKuKzbRBfnqco7bYLPboLgp0pDe3YM8-pCLVe_j2YjHF5gUrzqKAPUUln6oSMD03O3Fds2cjnve_VGBou6a-d13YCGkiDF9yUv9w7IzuzfhL94tTQsEWRFyrq9yrVK3M2lW-y2h04J9cv48KmrTY-XvLoALk31rptoh203X71q_dzg0hjTZnKX3bE-CT-oCXaPDSC_z7aPbdbFA_aDeMYtzzjyjPd4xjueccszbnjG-zzjLc94kfGGZ7zlGW95xjue8T7PeMezh2w6Opy8Hzu2kYeTeCKsHMB_fBpplP5KCdT0kYZQJh5krgR0oUXqZn4aDLVK9iM9lEkwDNHqBNS8qULnT_qP2FZe5PCEcZlFQSJc1FMKhOuCznwV0O5tLan_7f4ue9284HhV12uJ0c8lRGJCJDaI7LJXzbuPUZzSGpnKodis6UaPCiB5ONLjGpR2nAbEpzdeecZ2OgI_Z1tVuYEXaLRW-qXhyi8h9aLy
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risk+Factors+for+Unfavorable+Functional+Outcome+after+Endovascular+Treatment+of+Cerebral+Vasospasm+following+Aneurysmal+Subarachnoid+Hemorrhage&rft.jtitle=American+journal+of+neuroradiology+%3A+AJNR&rft.au=Thaler%2C+Christian&rft.au=Tokareva%2C+Bogdana&rft.au=Wentz%2C+Rabea&rft.au=Heitkamp%2C+Christian&rft.date=2025-03-04&rft.eissn=1936-959X&rft.volume=46&rft.issue=3&rft.spage=495&rft_id=info:doi/10.3174%2Fajnr.A8511&rft_id=info%3Apmid%2F40015973&rft.externalDocID=40015973
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0195-6108&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0195-6108&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0195-6108&client=summon